Will Pacira Pharmaceuticals, Inc. (PCRX) Short Squeeze Soon? The Stock Formed a Double Top Chart Pattern

November 10, 2018 - By Richard Conner

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Logo

Investors sentiment is 0.93 in 2018 Q2. Its the same as in 2018Q1. It is the same, as 26 investors sold Pacira Pharmaceuticals, Inc. shares while 46 reduced holdings. only 20 funds opened positions while 47 raised stakes. 40.41 million shares or 3.30% less from 41.78 million shares in 2018Q1 were reported.
Great West Life Assurance Can stated it has 3,835 shares. Keybank National Association Oh has 8,411 shares. Trexquant Lp stated it has 0.09% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Credit Suisse Ag holds 0% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 41,441 shares. Benjamin F Edwards & Incorporated accumulated 3,826 shares. Partner Inv L P owns 38,244 shares. Fincl Bank Of Mellon Corp owns 222,286 shares or 0% of their US portfolio. Riverpark Advsr Ltd Liability owns 29,071 shares for 0.19% of their portfolio. New York State Common Retirement Fund has invested 0.01% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Rock Springs Capital Mgmt L P invested 1.48% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Aqr Management Llc stated it has 25,234 shares or 0% of all its holdings. Segall Bryant & Hamill Llc holds 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 16,671 shares. Jefferies Ltd invested in 0% or 3,396 shares. Point72 Asset Management Limited Partnership has 101,636 shares for 0.01% of their portfolio. Canada Pension Plan Board holds 228,186 shares.

Since May 15, 2018, it had 1 insider buy, and 10 insider sales for $1.97 million activity. Weiland Robert J. also sold $12,316 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares. On Monday, June 4 the insider Riker Lauren Bullaro sold $26,449. 18,406 shares valued at $667,764 were sold by STACK DAVID M on Wednesday, June 6. On Monday, June 4 HASTINGS PAUL J sold $26,137 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) or 771 shares. 1,367 shares were sold by Scranton Richard, worth $45,138. Shares for $23,378 were sold by Reinhart Charles A. III.

The chart of Pacira Pharmaceuticals, Inc. (PCRX) shows a double top with $51.01 target or 3.00 % above today’s $49.52 share price. The 6 months chart pattern indicates low risk for the $2.04B company. It was reported on Nov, 10 by Finviz.com. If the $51.01 price target is reached, the company will be worth $61.08 million more. Double tops are rare but powerful chart patterns.

The stock decreased 2.81% or $1.43 during the last trading session, reaching $49.52. About 389,378 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has risen 23.87% since November 10, 2017 and is uptrending. It has outperformed by 8.25% the S&P500.

Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on November, 14. They expect $-0.07 EPS, up 36.36 % or $0.04 from last year’s $-0.11 per share. After $0.07 actual EPS reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -200.00 % negative EPS growth.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Ratings Coverage

Among 11 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 4 have Buy rating, 2 Sell and 5 Hold. Therefore 36% are positive. Pacira Pharmaceuticals had 13 analyst reports since May 29, 2018 according to SRatingsIntel. BMO Capital Markets maintained the stock with “Market Perform” rating in Friday, November 2 report. The firm earned “Market Outperform” rating on Friday, November 2 by JMP Securities. The firm has “Outperform” rating by Wedbush given on Monday, August 6. Barclays Capital maintained the stock with “Overweight” rating in Monday, August 6 report. Mizuho maintained it with “Hold” rating and $3100 target in Tuesday, May 29 report. The rating was upgraded by Needham to “Buy” on Friday, August 3. Wedbush maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Monday, June 18 with “Buy” rating. Bank of America downgraded the shares of PCRX in report on Monday, August 6 to “Neutral” rating. The company was maintained on Friday, November 2 by JP Morgan. Canaccord Genuity maintained the shares of PCRX in report on Tuesday, October 2 with “Hold” rating.

More important recent Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) news were published by: Nasdaq.com which released: “Pacira Pharmaceuticals to Present at Healthcare Conferences in November” on November 08, 2018, also Nasdaq.com published article titled: “Report: Developing Opportunities within Rayonier Advanced Materials, Health Insurance Innovations, Columbus …”, Globenewswire.com published: “Pacira Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results” on November 01, 2018. More interesting news about Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was released by: Nasdaq.com and their article: “Recent Analysis Shows Repligen, SpartanNash, AZUL SA, Pacira Pharmaceuticals, Ichor, and Scorpio Tankers Market …” with publication date: October 17, 2018.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $2.04 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News